Pyoderma gangrenosum
Pyoderma gangrenosum se yon maladi po ki ra, enflamatwa kote pustul ki fè lapenn oswa nodil vin maladi ilsè ki grandi piti piti. Pyoderma gangrenosum pa enfektye. Tretman yo ka gen ladan kortikoterapi, ciclosporin, oswa divès kalite antikò monoklonal. Menmsi li ka afekte moun nenpòt ki laj, li sitou afekte moun nan 40s ak 50s yo.
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Sou janm yon moun ki gen kolit ilsè.
References
Pyoderma gangrenosum se yon maladi po ki ra ki lakòz maladi ilsè ki fè lapenn ak kwen wouj oswa koulè wouj violèt. Li klase kòm yon maladi enflamatwa epi li fè pati yon gwoup ki rele dèrmatoz netrofil. Kòz pyoderma gangrenosum a konplèks, ki enplike pwoblèm ak iminite natirèl ak adaptasyon nan moun ki gen tandans jenetik. Dènyèman, chèchè yo te konsantre sou pileu cheve a kòm yon potansyèl pwen depa maladi a.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum se yon maladi po ki ra ki lakòz maladi ilsè ki fè lapenn anpil. Pandan ke nou pa byen konprann kòz li yo, nou konnen li enplike aktivite ogmante nan sèten selil iminitè. Trete maladi a pa toujou fasil. Nou gen divès kalite dwòg ki siprime sistèm iminitè a oswa modifye aktivite li yo. Ansanm sa yo, nou tou konsantre sou trete blesi yo ak jere doulè. Corticosteroids ak cyclosporine yo souvan premye chwa pou tretman, men dènyèman, te gen plis rechèch sou itilizasyon terapi byolojik tankou inibitè TNF-α. Byolojik sa yo de pli zan pli pi pito, espesyalman nan pasyan ki gen lòt kondisyon enflamatwa, epi yo ap itilize pi bonè nan pwosesis maladi a.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
